Therapeutic Asset Ratings

188 results matching 1 filter

133,990 assets · 8,802 sponsors · 3,128 indications

Methodology v0.2

Asset	Sponsor	Phase	Rating
Cobimetinib Thyroid Cancer, Papillary	Cancer Research UK	P2/3	B (56)
Cobimetinib Thyroid Carcinoma, Anaplastic	Cancer Research UK	P2/3	B (56)
Dabrafenib Erdheim-Chester Disease	Cancer Research UK	P2/3	B (56)
Dabrafenib Langerhans Cell Histiocytosis (LCH)	Cancer Research UK	P2/3	B (56)
Dabrafenib Laryngeal Neoplasms	Cancer Research UK	P2/3	B (56)
Dabrafenib Lymphoproliferative Disorders	Cancer Research UK	P2/3	B (56)
Dabrafenib Solid Tumour	Cancer Research UK	P2/3	B (56)
Dabrafenib Thyroid Carcinoma, Anaplastic	Cancer Research UK	P2/3	B (56)
Dabrafenib Thyroid Carcinoma, Papillary	Cancer Research UK	P2/3	B (56)
gsk1120212 Erdheim-Chester Disease	Cancer Research UK	P2/3	B (56)
gsk1120212 Langerhans Cell Histiocytosis (LCH)	Cancer Research UK	P2/3	B (56)
gsk1120212 Laryngeal Neoplasms	Cancer Research UK	P2/3	B (56)
gsk1120212 Lymphoproliferative Disorders	Cancer Research UK	P2/3	B (56)
gsk1120212 Solid Tumour	Cancer Research UK	P2/3	B (56)
gsk1120212 Thyroid Carcinoma, Papillary	Cancer Research UK	P2/3	B (56)
VEMURAFENIB Multiple Myeloma	Cancer Research UK	P2/3	B (56)
ALECTINIB Neuroblastoma	Cancer Research UK	P2/3	CCC (55)
Atezolizumab Endometrial Neoplasms	Cancer Research UK	P2/3	CCC (55)
Atezolizumab Solid Tumours	Cancer Research UK	P2/3	CCC (55)
Capmatinib Neoplasms by Histologic Type	Cancer Research UK	P2/3	CCC (55)
Cobimetinib Multiple Myeloma	Cancer Research UK	P2/3	CCC (55)
gsk1120212 Colorectal Neoplasms	Cancer Research UK	P2/3	CCC (55)
IMMUNOGLOBULIN G1, ANTI-(HUMAN NEU (RECEPTOR)) (HUMAN-MOUSE MONOCLONAL 2C4 HEAVY CHAIN), DISULFIDE WITH HUMAN-MOUSE MONOCLONAL 2C4 .KAPPA.-CHAIN, DIMER Solid Tumour	Cancer Research UK	P2/3	CCC (55)
TRASTUZUMAB Solid Tumour	Cancer Research UK	P2/3	CCC (55)
VEMURAFENIB Erdheim-Chester Disease	Cancer Research UK	P2/3	CCC (55)

Showing 51 to 75 of 188 assets

PreviousPage 3 of 8Next